AML

Bexmarilimab shows encouraging results when combined with standard of care treatments for patients with acute myeloid leukemia and myelodysplastic syndromes.

Based on the recommendation of an independent data monitoring committee and positive topline data, accrual in the KMT2A-rearranged cohorts of the AUGMENT-101 trial of revumenib will be stopped.

For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.

According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia.

Allogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.

Roland Walter, MD, PhD, and Johannes Schetelig, MD, debated on the sequencing of allogeneic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.

There was no difference in outcomes observed with intensive vs non-intensive consolidation chemotherapy regimens before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.

Triplet therapy regimens now are on the horizon for patients with AML, thanks to ongoing research into targeted therapies.

Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.

Johannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia/

Adaptation of improved methods of MRD detection are needed to better define this population at risk.

The phase 1/2 BEXMAB study is investigating the combination of bexmarilimab with standard of care in patients with hematologic malignancies.

In an interview, Jamie L. Koprivnikar, MD, discussed the importance of a machine learning approach to genomic testing in AML.

A pause on trials of magrolimab in acute myeloid leukemia will affect the screening and enrollment of patients.

Ziftomenib showed safety and efficacy in heavily pretreated patients with comutations and NPM1-mutated, relapsed/refractory acute myeloid leukemia.

Gilteritinib can be a promising bridge to allogeneic hematopoietic stem cell transplantation, according to data at the European Society for Blood and Marrow Transplantation 49th Annual Meeting.

The phase 3 QuANTUM-First trial showed that quizartinib plus chemotherapy with or without allogeneic hematopoietic stem cell transplant improved overall survival in patients with acute myeloid leukemia with a FLT3-ITD mutation.

In an interview with Targeted Oncology, Mitul Gandhi, MD, reviewed the latest guideline recommendations for the workup and treatment of acute myeloid leukemia.

Primary results from the phase 1 COVALENT 101 study demonstrate the potential of BMF-219 to induce responses in patients with various relapsed or refractory leukemias/lymphomas, including acute myeloid leukemia.

Data from the phase 3 QuANTUM-First trial have led the FDA to approve quizartinib with or without standard chemotherapy for the treatment. of FLT3-ITD-mutant acute myeloid leukemia .

New duration of remission data add to a growing body of clinical evidence supporting the development of APVO436 in combination therapy for patients with acute myeloid leukemia.

In an interview, Harry Erba, MD, PhD, compared ziftomenib with other Menin inhibitors and discussed data from the phase 1/2 trial evaluating the menin-KMT2A inhibitor in patients with AML.

In an interview with Targeted Oncology, Jorge Cortes, MD, highlights the use of olutasidenib in patients with relapsed/refractory acute myeloid leukemia.

The phase 1 study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of KT-253 monotherapy in patients with acute myeloid leukemias.

A time-based pathway to final analysis has been cleared by the FDA to evaluate the effect of uproleselan on relapsed/refractory acute myeloid leukemia.